Nashwa Gabra

Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial

Stefano Del Prato, Steven E. Kahn, Imre Pávó et al. · The Lancet · 2021 · 642 citations

Medicine, Pharmacology, Pharmacotherapy +16

Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial

Markus P. Schlaich, M Bellet, Michael A. Weber et al. · The Lancet · 2022 · 227 citations · Full text

Medicine, Cardiology, Pharmacology +14

Effect of Bamlanivimab vs Placebo on Incidence of COVID-19 Among Residents and Staff of Skilled Nursing and Assisted Living Facilities

Myron S. Cohen, Ajay Nirula, Mark J. Mulligan et al. · JAMA · 2021 · 208 citations · Full text

Medicine, Infectious Diseases, Preventive Medicine +10

RNA Interference With Zilebesiran for Mild to Moderate Hypertension

George L. Bakris, Manish Saxena, Anil Gupta et al. · JAMA · 2024 · 116 citations · Full text

Life Sciences, Molecular Biology, Pharmacology +17

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

Erin A. Bohula, Benjamin M. Scirica, Silvio E. Inzucchi et al. · The Lancet · 2018 · 95 citations · Full text

Medicine, Endocrinology, Pharmacology +14